CU20190020A7 - 1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico - Google Patents

1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico

Info

Publication number
CU20190020A7
CU20190020A7 CU2019000020A CU20190020A CU20190020A7 CU 20190020 A7 CU20190020 A7 CU 20190020A7 CU 2019000020 A CU2019000020 A CU 2019000020A CU 20190020 A CU20190020 A CU 20190020A CU 20190020 A7 CU20190020 A7 CU 20190020A7
Authority
CU
Cuba
Prior art keywords
muscarinergic
carboxamides
receptor
substituted
oxides
Prior art date
Application number
CU2019000020A
Other languages
English (en)
Other versions
CU24618B1 (es
Inventor
Arapinis Dr Melissa Boultadakis
Dr Markus Brechmann
Dr Till Freudenberger
Dr Maximilian Andreas Kullman
Dr Tobias Marquardt
Thomas Mondritzki
Dr Alexander Straub
Dr Henrik Teller
Dr Hanna Tinel
Dr Alexandros Vakalopoulos
Dr Matthias Beat Wittwer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16188728.6A external-priority patent/EP3296298A1/de
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20190020A7 publication Critical patent/CU20190020A7/es
Publication of CU24618B1 publication Critical patent/CU24618B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

<p>La presente solicitud se refiere a nuevas 1-arilnaftiridin-3-carboxamidas 7-sustituidas y sus N-óxidos, sales, solvatos, sales de los N-óxidos y solvatos de los N-óxidos y sales, así como un procedimiento para prepararlas y medicamentos que las comprenden solas o en combinaciones, que resultan ser moduladores alostéricos positivos, potentes, del receptor M2 muscarinérgico y como tales son adecuadas para el tratamiento y/o la prevención de trastornos cardiovasculares y/o trastornos renales.</p> <p>ESPACIO PARA LA FÓRMULA</p>
CU2019000020A 2016-09-14 2017-09-06 1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico CU24618B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16188728.6A EP3296298A1 (de) 2016-09-14 2016-09-14 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
EP16202509 2016-12-06
PCT/EP2017/072339 WO2018050510A1 (de) 2016-09-14 2017-09-06 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung

Publications (2)

Publication Number Publication Date
CU20190020A7 true CU20190020A7 (es) 2019-11-04
CU24618B1 CU24618B1 (es) 2022-08-09

Family

ID=59966701

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000020A CU24618B1 (es) 2016-09-14 2017-09-06 1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico

Country Status (40)

Country Link
US (3) US10927109B2 (es)
EP (1) EP3512849B1 (es)
JP (1) JP7295019B2 (es)
KR (2) KR20190046851A (es)
CN (4) CN109689656B (es)
AU (1) AU2017326297B2 (es)
BR (1) BR112019004982A2 (es)
CA (1) CA3036497A1 (es)
CL (1) CL2019000670A1 (es)
CO (1) CO2019002361A2 (es)
CR (1) CR20190131A (es)
CU (1) CU24618B1 (es)
CY (1) CY1124492T1 (es)
DK (1) DK3512849T3 (es)
DO (1) DOP2019000060A (es)
EC (1) ECSP19018116A (es)
ES (1) ES2887674T3 (es)
GE (1) GEP20217332B (es)
HR (1) HRP20211396T1 (es)
HU (1) HUE056343T2 (es)
IL (1) IL265106B (es)
JO (1) JOP20190045A1 (es)
LT (1) LT3512849T (es)
MA (1) MA46235B1 (es)
MX (1) MX2019003007A (es)
MY (1) MY196473A (es)
NI (1) NI201900023A (es)
NZ (1) NZ751297A (es)
PE (1) PE20190803A1 (es)
PH (1) PH12019500535A1 (es)
PL (1) PL3512849T3 (es)
RS (1) RS62299B1 (es)
SG (1) SG11201901973RA (es)
SI (1) SI3512849T1 (es)
TN (1) TN2019000083A1 (es)
TW (1) TWI758325B (es)
UA (1) UA125627C2 (es)
UY (1) UY37403A (es)
WO (1) WO2018050510A1 (es)
ZA (1) ZA201902325B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3692991A1 (de) 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
US10519154B2 (en) 2016-07-11 2019-12-31 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN115605609A (zh) * 2020-04-08 2023-01-13 拜耳公司（De） 使用rt-pcr的病毒感染的快速检测

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
JPS60228479A (ja) 1984-04-26 1985-11-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
DE4301246A1 (de) 1993-01-19 1994-07-21 Bayer Ag Chinolon- und Naphthyridoncarbonsäurederivate
JP2758722B2 (ja) * 1993-08-13 1998-05-28 ドング ホワ ファーマシューチカル インダストリアル カンパニー，リミテッド 新規キノロンカルボン酸誘導体
JP3448305B2 (ja) 1996-11-28 2003-09-22 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩及びこれを有効成分とする医薬
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
AU2002361493A1 (en) 2001-12-13 2003-06-23 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005012561A (ja) 2003-06-19 2005-01-13 Sony Corp 画像処理装置、画像処理方法および画像投射装置
EP1650192A4 (en) 2003-07-24 2007-03-21 Astellas Pharma Inc QUINOLONE DERIVATIVE OR SALT THEREOF
WO2005026165A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
JP2007513955A (ja) 2003-12-09 2007-05-31 バーテックス　ファーマシューティカルズ　インコーポレイテッド ナフチリジン誘導体およびそれらのムスカリン受容体の調節剤としての使用
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
WO2010093341A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica N.V. C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
CN102651970B (zh) 2009-12-17 2014-11-12 默沙东公司 喹啉酰胺m1受体正性变构调节剂
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN103360388B (zh) 2012-04-10 2017-11-14 江苏先声药业有限公司 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途
CN102964350A (zh) 2012-09-20 2013-03-13 杨文� 一种7-六氢吡咯并[1,2-a]吡嗪基喹诺酮羧酸衍生物及其在治疗幽门螺杆菌感染应用
CN103183676B (zh) 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
MX2017005479A (es) 2014-11-03 2017-07-04 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos.
JP2017538689A (ja) 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
KR101837047B1 (ko) 2015-06-09 2018-03-09 제일약품주식회사 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
CA2988502A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Nuclear receptor modulators
EP3692991A1 (de) 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
US10519154B2 (en) 2016-07-11 2019-12-31 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.

Also Published As

Publication number Publication date
MA46235B1 (fr) 2021-10-29
CN115429798A (zh) 2022-12-06
CR20190131A (es) 2019-05-15
LT3512849T (lt) 2021-08-25
EP3512849B1 (de) 2021-06-23
SI3512849T1 (sl) 2021-10-29
DK3512849T3 (da) 2021-08-16
CO2019002361A2 (es) 2019-06-19
JOP20190045A1 (ar) 2019-03-14
AU2017326297A1 (en) 2019-03-28
TWI758325B (zh) 2022-03-21
CN115554294A (zh) 2023-01-03
US20210261541A1 (en) 2021-08-26
GEP20217332B (en) 2021-12-10
DOP2019000060A (es) 2019-04-15
MA46235A (fr) 2021-04-14
IL265106B (en) 2022-05-01
TN2019000083A1 (en) 2020-07-15
ES2887674T3 (es) 2021-12-27
RS62299B1 (sr) 2021-09-30
US11472803B2 (en) 2022-10-18
WO2018050510A1 (de) 2018-03-22
EP3512849A1 (de) 2019-07-24
CY1124492T1 (el) 2022-07-22
HRP20211396T1 (hr) 2021-12-10
MY196473A (en) 2023-04-12
ECSP19018116A (es) 2019-03-29
US20220089591A1 (en) 2022-03-24
KR20190046851A (ko) 2019-05-07
PL3512849T3 (pl) 2021-11-29
AU2017326297B2 (en) 2021-07-29
NI201900023A (es) 2019-05-23
MX2019003007A (es) 2019-07-18
US20190263805A1 (en) 2019-08-29
ZA201902325B (en) 2022-03-30
BR112019004982A2 (pt) 2019-08-20
UA125627C2 (uk) 2022-05-04
TW201811785A (zh) 2018-04-01
CN109689656A (zh) 2019-04-26
CA3036497A1 (en) 2018-03-22
KR20230035437A (ko) 2023-03-13
US10927109B2 (en) 2021-02-23
CN109689656B (zh) 2022-10-04
JP2019534320A (ja) 2019-11-28
UY37403A (es) 2018-04-30
JP7295019B2 (ja) 2023-06-20
PE20190803A1 (es) 2019-06-10
CU24618B1 (es) 2022-08-09
CN115477649A (zh) 2022-12-16
SG11201901973RA (en) 2019-04-29
HUE056343T2 (hu) 2022-02-28
PH12019500535A1 (en) 2019-11-04
NZ751297A (en) 2022-12-23
CL2019000670A1 (es) 2019-08-02

Similar Documents

Publication Publication Date Title
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
CL2018002794A1 (es) Compuestos bicíclicos
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CY1122227T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
ECSP17023281A (es) Inhibidores de mk2 y sus usos
CU20190020A7 (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas como moduladores del receptor m2 muscarinérgico
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
UY36327A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y sus usos en el tratamiento de una afección mediada por el receptor de glucocorticoides
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
UY34719A (es) Proceso para la producción de inhibidores de crr
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
TW201612253A (en) High wet fast disperse dyes and mixtures thereof